Comparing SYS6002 to chemotherapy for advanced bladder cancer
Treatments studied
Part of Cancer clinical trials.
This study tests a new drug called SYS6002 against standard chemotherapy for people with advanced bladder cancer that has grown after previous treatments. The goal is to see if SYS6002 can help slow the cancer better than chemotherapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have advanced bladder cancer (urothelial cancer) that has spread or cannot be removed by surgery.
- You have already tried platinum-based chemotherapy and a PD-(L)1 inhibitor, but the cancer got worse.
- You have at least one tumor that can be measured on scans.
- You are not pregnant or breastfeeding, and if you are fertile, you agree to use contraception during and after the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called BL-B01D1 against standard chemotherapy for people with advanced bladder cancer that has stopped responding to platinum chemo and immunotherapy. The goal is to see if the new drug works better.
This Phase 2 study tests giving standard chemotherapy first, then immunotherapy, followed by major surgery to remove the bladder/urinary tumor and nearby lymph nodes. It’s for people with locally advanced urothelial cancer whose cancer has at least not worsened after initial chemotherapy.
This trial is testing a new combination of two drugs (9MW2821 and toripalimab) against standard chemotherapy for people with advanced bladder cancer that has not been treated before. The goal is to see if this new approach works better at shrinking tumors or slowing the cancer's growth.
This trial tests a new experimental drug combination (BL-B01D1 with a PD-1 immunotherapy) for advanced bladder cancer that has not yet been treated with whole-body therapy. The goal is to see if this combination can shrink tumors and help people live longer without their cancer getting worse.
This trial compares a new investigational drug called SYS6002 with an already approved treatment called PADCEV for advanced urothelial carcinoma (a type of bladder or urinary tract cancer). The goal is to see if SYS6002 can be as effective or better than PADCEV at slowing cancer growth.
This trial tests a new drug called SYS6002 (an antibody-drug conjugate that targets cancer cells) against standard chemotherapy for cervical cancer that has spread or returned after prior treatment. The goal is to see if it can shrink tumors and help you live longer, possibly with fewer side effects.
Hear when a new Urothelial Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.